Q-omics provides the consensus-scored IL17D profile across patient tissues and cancer cell-line models. IL17D expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, IL17D is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, IL17D RNA expression shows 18,578 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, LUAD, and TGCT as cancer lineages where IL17D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL17D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL17D survival associations across molecular data types. IL17D RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL17D RNA expression–survival associations across cancer types. High IL17D expression shows unfavorable associations in KICH, ACC, KIRP, READ and SKCM, but favorable associations in LGG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for IL17D RNA expression.
This table summarizes IL17D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IL17D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL17D shows lower tumor expression in LUAD, THCA, BLCA, LUSC and HNSC and higher tumor expression in LIHC. The LUAD box plot shows higher IL17D RNA expression in normal versus tumor tissue (log2 FC = −1.553, t-test p < 0.001).
This table shows molecular features associated with IL17D in patient tissues and cancer cell lines. In patient samples, IL17D shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IL17D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
